摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

2,5-二氮杂双环[2.2.2]辛烷双盐酸盐 | 1192-92-3

中文名称
2,5-二氮杂双环[2.2.2]辛烷双盐酸盐
中文别名
2,5-二氮杂双环[2.2.2]辛烷二盐酸盐
英文名称
2,5-Diazabicyclo[2.2.2]octane dihydrochloride
英文别名
2,5-diazabicyclo[2.2.2]octane;dihydrochloride
2,5-二氮杂双环[2.2.2]辛烷双盐酸盐化学式
CAS
1192-92-3
化学式
C6H14Cl2N2
mdl
——
分子量
185.09
InChiKey
MYIPGNFIOPNJBA-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

计算性质

  • 辛醇/水分配系数(LogP):
    0.55
  • 重原子数:
    10
  • 可旋转键数:
    0
  • 环数:
    3.0
  • sp3杂化的碳原子比例:
    1.0
  • 拓扑面积:
    24.1
  • 氢给体数:
    4
  • 氢受体数:
    2

安全信息

  • 海关编码:
    2933990090

SDS

SDS:202caf3eea94c3d1ef07d873061aee51
查看

反应信息

  • 作为反应物:
    描述:
    参考文献:
    名称:
    FUSED PYRAZINE COMPOUNDS USEFUL FOR THE TREATMENT OF DEGENERATIVE AND INFLAMMATORY DISEASES
    摘要:
    本发明披露了一种具有以下式子表示的Novel [1.2.4]triazolo [1,5-a] pyrazine和imidazo [1,2-a] pyrazine化合物:这些化合物可以制备成药物组合物,并可用于预防和治疗哺乳动物包括人类的各种疾病,包括但不限于疼痛,炎症等。
    公开号:
    US20090286798A1
点击查看最新优质反应信息

文献信息

  • Rifamycin analogs and uses thereof
    申请人:van Duzer H. John
    公开号:US20050043298A1
    公开(公告)日:2005-02-24
    The present invention features rifamycin analogs that can be used as therapeutics for treating or preventing a variety of microbial infections. In one form, the analogs are acetylated at the 25-position, as is rifamycin. In another form, the analogs are deacetylated at the 25-position. In yet other forms, benzoxazinorifamycin, benzthiazinorifamycin, and benzdiazinorifamycin analogs are derivatized at various positions of the benzene ring, including 3′-hydroxy analogs, 4′-and/or 6′ halo and/or alkoxy analogs, and various 5′ substituents that incorporate a cyclic amine moiety.
    这项发明涉及利福霉素类似物,可用作治疗或预防各种微生物感染的治疗药物。在一种形式中,这些类似物在25位点上乙酰化,就像利福霉素一样。在另一种形式中,这些类似物在25位点上去乙酰化。在其他形式中,苯并噁唑利福霉素、苯并噻唑利福霉素和苯并二唑利福霉素类似物在苯环的各个位置上进行衍生化,包括3'-羟基类似物、4'-和/或6'卤代和/或烷氧基类似物,以及各种包含环胺基团的5'取代基。
  • FUSED PYRAZINE COMPOUNDS USEFUL FOR THE TREATMENT OF DEGENERATIVE AND INFLAMMATORY DISEASES
    申请人:Andrews Martin James Inglis
    公开号:US20090286798A1
    公开(公告)日:2009-11-19
    Novel[1.2.4]triazolo[1,5-a]pyrazine and imidazo[1,2-a]pyrazine compounds are disclosed that have a formula represented by the following: The compounds may be prepared as pharmaceutical compositions, and may be used for the prevention and treatment of a variety of conditions in mammals including humans, including by way of non-limiting example, pain, inflammation, and others.
    揭示了具有以下表示的公式的新型[1.2.4]三唑并咪唑[1,2-a]吡嗪化合物:这些化合物可以制备为药物组合物,并可用于哺乳动物包括人类的预防和治疗多种疾病,包括但不限于疼痛、炎症等。
  • Substituted Nicotinamide Compounds
    申请人:Hamblett Christopher
    公开号:US20090105264A1
    公开(公告)日:2009-04-23
    The present invention relates to a novel class of substituted nicotinamides. These compounds can inhibit histone deacetylase and are suitable for use in selectively inducing terminal differentiation, and arresting cell growth and/or apoptosis of neoplastic cells, thereby inhibiting proliferation of such cells. Thus, the compounds of the present invention are useful in treating a patient having a tumor characterized by proliferation of neoplastic cells. The compounds of the invention may also be useful in the prevention and treatment of TRX-mediated diseases, such as autoimmune, allergic and inflammatory diseases, and in the prevention and/or treatment of diseases of the central nervous system (CNS), such as neurodegenerative diseases. The present invention further provides pharmaceutical compositions comprising the compounds of the instant invention and safe dosing regimens of these pharmaceutical compositions, which are easy to follow, and which result in a therapeutically effective amount of these compounds in vivo.
    本发明涉及一类新型的替代烟酰胺化合物。这些化合物可以抑制组蛋白去乙酰化酶,适用于选择性诱导终末分化,并阻止肿瘤细胞的生长和/或凋亡,从而抑制这些细胞的增殖。因此,本发明的化合物在治疗具有以肿瘤细胞增殖为特征的患者方面是有用的。本发明的化合物还可能在预防和治疗TRX介导的疾病方面有用,如自身免疫、过敏和炎症性疾病,以及预防和/或治疗中枢神经系统(CNS)疾病,如神经退行性疾病。本发明还提供了包含本发明化合物的药物组合物,以及这些药物组合物的安全用药方案,易于遵循,并在体内产生这些化合物的治疗有效量。
  • Antibacterial agents
    申请人:Warner-Lambert Company
    公开号:US04571396A1
    公开(公告)日:1986-02-18
    Novel naphthyridine-, quinoline- and benzoxazine-carboxylic acids as antibacterial agents are described as well as methods for their manufacture, formulation, and use in treating bacterial infections including the description of certain novel intermediates used in the manufacture of the antibacterial agents.
    本文介绍了新型萘啶基、喹啉基和苯并噁嗪基羧酸作为抗菌剂,以及它们的制造、配方和治疗细菌感染的使用方法,包括用于制造抗菌剂的某些新型中间体的描述。
  • Substituted naphthyridine-, quinoline- and benzoxazine- carboxylic acids as antibacterial agents and processes for their production
    申请人:WARNER-LAMBERT COMPANY
    公开号:EP0159174A2
    公开(公告)日:1985-10-23
    Compounds of the formula wherein Z is in which R is hydrogen, alkyl of one to three carbon atoms, hydroxyalkyl of two or three carbon atoms, benzyl, or p-aminobenzyl; R' is hydrogen or alkanoyl of from one to three carbon atoms; W is O, NR, S, or CH; X is CH, CF, or N; Y is hydrogen, fluoro, or amino; R, is hydrogen, alkyl having from one to six carbon atoms or a cation; R2 is alkyl having from one to four carbon atoms, vinyl, haloalkyl, hydroxyalkyl having from two to four carbon atoms or cycloalkyl having three to six carbon atoms; R3 is hydrogen or alkyl having from one to three carbon atoms; R4 is hydrogen or alkyl from one to three carbon atoms; or a pharmaceutically acceptable acid addition or base salt thereof. Also described are processes for producing the compounds and novel intermediates used in the manufacture of the antibacterial agents.
    式中的化合物 其中 Z 是 其中 R 是氢、一至三个碳原子的烷基、二或三个碳原子的羟烷基、苄基或对氨基苄基;R'是氢或一至三个碳原子的烷酰基;W 是 O、NR、S 或 CH;X 是 CH、CF 或 N;Y 是氢、氟或氨基;R, 是氢、一至六个碳原子的烷基或阳离子;R2是具有一至四个碳原子的烷基、乙烯基、卤代烷基、具有二至四个碳原子的羟烷基或具有三至六个碳原子的环烷基;R3是氢或具有一至三个碳原子的烷基;R4是氢或具有一至三个碳原子的烷基;或其药学上可接受的酸加成盐或碱式盐。此外,还描述了用于生产抗菌剂的化合物和新型中间体的生产工艺。
查看更多